Skip to main content
Caplight Logo









GeneVentiv Therapeutics, Inc.

GeneVentiv Therapeutics, Inc.

Private
Raleigh, North CarolinaHealthcare & Life Scienceshttps://www.geneventiv.com/

Last Round

Grant

Apr 16, 2024

Total Funding Raised

$4.2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

GeneVentiv Therapeutics, Inc. is a drug discovery company that develops gene therapies designed to treat rare genetic disorders. The company's treatments address hemophilia and Pompe disease, aiming to provide long-lasting and effective solutions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2G

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

gene therapyhemophilia treatmentAAV gene therapyrare disease therapyhemophilia inhibitorsPompe disease treatmentcell and gene therapyCGTgene editinguniversal hemophilia therapyone-time treatmentAAV vectorgenetic medicineCas9 gene editingpre-clinical biotechFactor V gene therapyorphan drug developmentAAV manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GeneVentiv Therapeutics, Inc. Comparables

Compare GeneVentiv Therapeutics, Inc. with similar companies based on industry and business-model similarity.

GeneVentiv Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ASC Therapeutics
77%
Roche Holding
71%
Pfizer
69%

GeneVentiv Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 16, 2024
SeedSep 1, 2022
DebtJun 8, 2022
GrantMar 16, 2022

GeneVentiv Therapeutics, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors increased 47% MoM.

  • Mar 3, 2026

    Monthly visitors increased 126% MoM.

GeneVentiv Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GeneVentiv Therapeutics, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GeneVentiv Therapeutics, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersRaleigh, North Carolina
Employee Range4
Year Founded2020
Last FundingApr 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?